Mandate

Vinge advises AstraZeneca

January 30, 2013

Vinge has advised AstraZeneca in connection with the sale of its research facility in Södertälje to Acturum, a group formed by FAM, the Wallenber foundations’ management company, and PEAB. The transaction covers, among other things, real estate, laboratories, research projects and a significant number of laboratory equipment and is intended to create conditions for future research and enterprise within the entire filed of life science.

Vinge’s team consisted of responsible partner Malin Ohlin and associate Kristina Ekberg and also included partner Patrick Forslund and associates Daniel Unger, Johan Cederblad, Nazli Zia, Peter Alstergren, Claes Henriksson and project assistant Sara Andersson.

Related

Vinge advises Main Capital and Aritma in connection with the acquisition of Programekonomi

Vinge has advised Aritma International AS (“Aritma”), a Norwegian bank-connectivity and financial automation software provider, in connection with the acquisition of Programekonomi Svenska Aktiebolag.
October 09, 2025

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025